专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20200069809A1 PHARMACEUTICAL FORMULATION COMPRISING INCRETIN-INSULIN CONJUGATES 审中-公开
公开(公告)号：US20200069809A1
公开(公告)日：2020-03-05
申请号：US16607453
申请日：2018-05-14
申请人： Shuai SHI , Valentyn ANTOCHSHUK , Merck Sharp & Dohme Corp.
发明人： Shuai Shi , Valentyn Antochshuk
IPC分类号： A61K47/64 , A61K47/18 , A61K47/10 , A61K38/28 , A61K47/02 , A61P3/10 , A61K9/08 , A61K38/26 , A61K9/00
摘要： This disclosure relates to stable aqueous pharmaceutical formulations comprising a therapeutically effective amount of an incretin-insulin conjugate as well as methods of using the same, and aqueous pharmaceutical formulations containing an incretin-insulin conjugate which are stable and which provide a protracted pharmacodynamics profile, which include L-arginine HCl and phenol (or m-cresol) as stabilizing agents. The invention also provide a method of treating a patient or individual having a metabolic disease, comprising administering to the patient or individual an effective amount of any of the aqueous pharmaceutical formulations described

2. 发明授权

US11590237B2 Pharmaceutical formulation comprising incretin-insulin conjugates 有权
公开(公告)号：US11590237B2
公开(公告)日：2023-02-28
申请号：US16607453
申请日：2018-05-14
申请人： Merck Sharp & Dohme Corp. , Shuai Shi , Valentyn Antochshuk
发明人： Shuai Shi , Valentyn Antochshuk
IPC分类号： A61K38/28 , A61K47/64 , A61P3/10 , A61K9/00 , A61K9/08 , A61K38/26 , A61K47/02 , A61K47/10 , A61K47/18
摘要： This disclosure relates to stable aqueous pharmaceutical formulations comprising a therapeutically effective amount of an incretin-insulin conjugate as well as methods of using the same, and aqueous pharmaceutical formulations containing an incretin-insulin conjugate which are stable and which provide a protracted pharmacodynamics profile, which include L-arginine HCl and phenol (or m-cresol) as stabilizing agents. The invention also provide a method of treating a patient or individual having a metabolic disease, comprising administering to the patient or individual an effective amount of any of the aqueous pharmaceutical formulations described herein.

3. 发明申请

US20180318426A1 PHARMACEUTICAL FORMULATIONS COMPRISING INSULIN OR INSULIN ANALOGS CONJUGATED TO FUCOSE FOR PROVIDING A BASAL PHARMACODYNAMIC PROFILE 审中-公开
公开(公告)号：US20180318426A1
公开(公告)日：2018-11-08
申请号：US15966585
申请日：2018-04-30
申请人： MERCK SHARP & DOHME CORP.
发明人： Shuai Shi , Valentyn Antochshuk , Joseph Rizzo , Niels C. Kaarsholm
IPC分类号： A61K47/54 , A61K47/02 , A61K47/42 , A61K47/10 , A61K47/12 , A61K38/28 , A61P3/10
CPC分类号： A61K47/549 , A61K38/28 , A61K47/02 , A61K47/10 , A61K47/12 , A61K47/42 , A61P3/10
摘要： Disclosed is a pharmaceutical formulation comprising an insulin or insulin analog molecule covalently attached to at least one branched linker having a first arm and second arm, wherein the first arm is linked to a first ligand that includes a first saccharide and the second arm is linked to a second ligand that includes a second saccharide and wherein the first saccharide is fucose. The formulation is suitable for subcutaneous administration and provides a basal pharmacodynamic profile for the insulin oligosaccharide conjugate.

4. 发明申请

US20180318427A1 PHARMACEUTICAL FORMULATIONS COMPRISING INSULIN OR INSULIN ANALOGS CONJUGATED TO FUCOSE 审中-公开
公开(公告)号：US20180318427A1
公开(公告)日：2018-11-08
申请号：US15966602
申请日：2018-04-30
申请人： MERCK SHARP & DOHME CORP.
发明人： Shuai Shi , Valentyn Antochshuk , Joseph Rizzo
IPC分类号： A61K47/54 , A61K47/02 , A61K47/10 , A61K47/12 , A61K38/28 , A61P3/10
CPC分类号： A61K47/549 , A61K38/28 , A61K47/02 , A61K47/10 , A61K47/12 , A61P3/10
摘要： Disclosed is a pharmaceutical formulation comprising an insulin or insulin analog molecule covalently attached to at least one branched linker having a first arm and second arm, wherein the first arm is linked to a first ligand that includes a first saccharide and the second arm is linked to a second ligand that includes a second saccharide and wherein the first saccharide is fucose suitable for parenteral or subcutaneous administration and which is suitable for use in controlling post-prandial glucose levels in an individual.

5. 发明授权

US09649383B2 Liquid formulations for TNFR:Fc fusion proteins 有权
公开(公告)号：US09649383B2
公开(公告)日：2017-05-16
申请号：US14443557
申请日：2013-11-15
申请人： MERCK SHARP & DOHME CORP.
发明人： Ramesh S. Kashi , Shona P. Patel , Sarita Mittal , Ashwin Basarkar , Shuai Shi
IPC分类号： A61K38/17 , A61K47/26 , A61K47/18 , A61K47/12 , A61K47/22 , A61K47/02 , C07K14/715
CPC分类号： A61K47/26 , A61K38/1793 , A61K47/02 , A61K47/12 , A61K47/183 , A61K47/22 , C07K14/7151 , C07K2319/30
摘要： The invention provides stable liquid formulations for a recombinant biopharmaceutical protein comprising a soluble form of the human p75 TNF receptor fused to an Fe domain of a human immunoglobulin protein (TNFR:Fc). Typically, biopharmaceutical proteins such as monoclonal antibodies (mAbs) and immunoglobulin fusion proteins (e.g., immunoadhesion proteins) are produced by recombinant DNA technology in mammalian cell expression systems. In order to guarantee the reproducible clinical performance of a biopharmaceutical product, manufacturers have to deliver a product of consistent and reproducible quality.

6. 发明申请

US20200055938A1 FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES 审中-公开
公开(公告)号：US20200055938A1
公开(公告)日：2020-02-20
申请号：US16609961
申请日：2018-05-01
申请人： Merck Sharp & Dohme Corp.
发明人： Preeti G. Desai , Shuai Shi , Valentyn Antochshuk , Rubi Burlage , Smita Raghava
IPC分类号： C07K16/28 , A61K47/02 , A61K9/00
摘要： The present invention provides formulations of anti-LAG3 antibodies, and co-formulations of anti-PD-1 antibodies and anti-LAG3 antibodies, and their use in treating various disorders.

7. 发明申请

US20150290325A1 LIQUID FORMULATIONS FOR TNFR:Fc FUSION PROTEINS 有权
标题翻译：用于TNFR的液体制剂：Fc融合蛋白
公开(公告)号：US20150290325A1
公开(公告)日：2015-10-15
申请号：US14443557
申请日：2013-11-15
申请人： MERCK SHARP & DOHME CORP.
发明人： Ramesh S. Kashi , Shona P. Patel , Sarita Mittal , Ashwin Basarkar , Shuai Shi
IPC分类号： A61K47/26 , A61K47/18 , A61K47/12 , A61K47/22 , A61K38/17 , A61K47/02
CPC分类号： A61K47/26 , A61K38/1793 , A61K47/02 , A61K47/12 , A61K47/183 , A61K47/22 , C07K14/7151 , C07K2319/30
摘要： The invention provides stable liquid formulations for a recombinant biopharmaceutical protein comprising a soluble form of the human p75 TNF receptor fused to an Fe domain of a human immunoglobulin protein (TNFR:Fc). Typically, biopharmaceutical proteins such as monoclonal antibodies (mAbs) and immunoglobulin fusion proteins (e.g., immunoadhesion proteins) are produced by recombinant DNA technology in mammalian cell expression systems. In order to guarantee the reproducible clinical performance of a biopharmaceutical product, manufacturers have to deliver a product of consistent and reproducible quality.
摘要翻译：本发明提供用于重组生物药物蛋白质的稳定液体制剂，其包含与人免疫球蛋白（TNFR：Fc）的Fe结构域融合的人p75 TNF受体的可溶形式。通常，通过重组DNA技术在哺乳动物细胞表达系统中产生生物制药蛋白，例如单克隆抗体（mAb）和免疫球蛋白融合蛋白（例如免疫粘附蛋白）。为了保证生物制药产品的可重现的临床表现，制造商必须提供一致和可重复品质的产品。

8. 发明申请

US20110296330A1 METHOD AND APPARATUS FOR PROVIDING INDUSTRIAL PLANT INFORMATION 审中-公开
标题翻译：提供工业植物信息的方法和装置
公开(公告)号：US20110296330A1
公开(公告)日：2011-12-01
申请号：US12788812
申请日：2010-05-27
申请人： Shuai Shi
发明人： Shuai Shi
IPC分类号： G06F3/048
CPC分类号： G05B19/4184 , Y02P90/14 , Y02P90/86
摘要： The apparatus comprises a display module configured for setting, displaying, and removing marks in a distributed control system and an asset management system of the industrial plant; a mark definition module configured for defining attributes of a plurality of marks including a first mark and a second mark; and a synchronization module configured for selecting the second mark from among the plurality of marks for automatic display by the display module in one of: the DCS and the AMS when the first mark is set in the other of: the DCS and the AMS, based on attributes of the first mark and attributes of the second mark defined with the mark definition module; so as to provide appropriate information to at least one of: a distributed control system operator and an asset management system user. The method comprises setting a first mark in one of: a distributed control system and an asset management system of the industrial plant; and upon setting the first mark, automatically displaying at least a second mark in another of: the distributed control system and the asset management system; wherein attributes of the first mark and attributes of the second mark have been predefined to enable provision of appropriate information to at least one of: a distributed control system operator and an asset management system user.
摘要翻译：该装置包括：显示模块，用于在工业工厂的分布式控制系统和资产管理系统中设置，显示和移除标记; 标记定义模块，被配置为定义包括第一标记和第二标记的多个标记的属性; 以及同步模块，被配置为从所述多个标记中选择所述第二标记，以由所述显示模块在以下之一中的一个中选择以下之一：DCS和AMS，当所述第一标记被设置在所述DCS和AMS中时第一个标记的属性和用标记定义模块定义的第二个标记的属性; 以便向以下至少一个提供适当的信息：分布式控制系统操作员和资产管理系统用户。该方法包括设置工业厂房的分布式控制系统和资产管理系统之一的第一标记; 并且在设置第一标记时，在分布式控制系统和资产管理系统中的另一个中自动显示至少第二标记; 其中已经预定义了第一标记和第二标记的属性的属性，以便能够向以下至少一个提供适当的信息：分布式控制系统操作员和资产管理系统用户。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式